Copertina

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	David Uihwan Lee, Mohammed Rifat Shaik, Kuntal Bhowmick, Gregory Hongyuan Fan, Kimberly Schuster, Abdul Yousaf, Mohamed Refaat, Nishat Anjum Shaik, Ki Jung Lee, Sarah Yang, Aneesh Bahadur, Nathalie H. Urrunaga
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
di: Jung Eun Park, et al.
Pubblicazione: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
di: Sung Won Chung, et al.
Pubblicazione: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
di: Jian Wang, et al.
Pubblicazione: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
di: Deepak Joshi, et al.
Pubblicazione: (2024)

Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods
di: Nipun Verma, et al.
Pubblicazione: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index in predicting mortality and guiding prehabilitation
di: Sara J. Harris, et al.
Pubblicazione: (2024)

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests?
di: C. Gaume, et al.
Pubblicazione: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
di: C. Stephens
Pubblicazione: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
di: Nobuharu Tamaki, et al.
Pubblicazione: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
di: Nobuharu Tamaki, et al.
Pubblicazione: (2024)

An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
di: Mar Riveiro‐Barciela, et al.
Pubblicazione: (2024)

Editorial: The future of managing drug induced liver injury
di: Amanda Nicoll
Pubblicazione: (2024)

Review article: Oesophageal disorders in chronic liver disease
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
di: Yewan Park, et al.
Pubblicazione: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index (DASI) in predicting mortality and guiding prehabilitation. Authors' reply
di: Matthew J. Armstrong, et al.
Pubblicazione: (2024)

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests? Authors' reply
di: Maria Gabriela Fernandes Dezan, et al.
Pubblicazione: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
di: Shusuke Kumazaki, et al.
Pubblicazione: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
di: Yaomin Wang, et al.
Pubblicazione: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
di: Zhuo Li, et al.
Pubblicazione: (2024)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
di: Xianhua Mao, et al.
Pubblicazione: (2024)

The impact of macro‐ and micro‐steatosis on the outcomes of patients who undergo liver transplant: Analysis of the UNOS‐STAR database
di: David Uihwan Lee, et al.
Pubblicazione: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
di: Parminder Kaur, et al.
Pubblicazione: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
di: Mohamed I. Elsaid, et al.
Pubblicazione: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
di: Richie Manikat, et al.
Pubblicazione: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
di: Ivan Arcari, et al.
Pubblicazione: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
di: Nina Dominik, et al.
Pubblicazione: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
di: Abdel‐Aziz Shaheen, et al.
Pubblicazione: (2024)

Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
di: Donghee Kim, et al.
Pubblicazione: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Characterisation of an outbreak of acute liver injury after ingestion of plant‐based food supplement
di: Gina Choi, et al.
Pubblicazione: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
di: Basile Njei, et al.
Pubblicazione: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
di: Manya Prasad, et al.
Pubblicazione: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
di: Nabil Noureddin, et al.
Pubblicazione: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
di: Stuart McPherson, et al.
Pubblicazione: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
di: Eunice X. X. Tan, et al.
Pubblicazione: (2024)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
di: Victoria T. Kronsten, et al.
Pubblicazione: (2024)